Tumor Phosphatidylinositol-3-Kinase Signaling and Development of Metastatic Disease in Locally Advanced Rectal Cancer

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ree, Anne Hansen ^a,b   Kristensen, Annette Torgunrud ^c   Saelen, Marie Grøn ^b,c   de Wijn, Rik ^d   Edvardsen, Hege ^c   Jovanovic, Jovana ^a,b   Abrahamsen, Torveig Weum ^c   Dueland, Svein ^e   Flatmark, Kjersti ^c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d PamGene International BV   (Netherlands)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADVANCED CANCER; ARTICLE; BRAF GENE; CANCER GROWTH; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FOLLOW UP; HUMAN; HUMAN TISSUE; K RAS GENE; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS FREE SURVIVAL; MUTATOR GENE; PIK3CA GENE; POINT MUTATION; RECTUM CANCER; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; DISEASE-FREE SURVIVAL; HUMANS; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; RECTAL NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84870667386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050806     Document Type: Article

References (38)

1. Hunter T, (2000) Signaling-2000 and beyond. Cell 100: 113-127.
2. Vogelstein B, Kinzler KW, (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
3. Valentini V, Beets-Tan R, Borras JM, Krivokapic Z, Leer JW, et al. (2008) Evidence and research in rectal cancer. Radiother Oncol 87: 449-474.
4. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R, (2009) Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Anal Biochem. 387: 150-161.
5. Thiele A, Stangl GI, Schutkowski M, (2011) Deciphering enzyme function using peptide arrays. Mol Biotechnol 49: 283-305.
6. Sikkema AH, den Dunnen WF, Diks SH, Peppelenbosch MP, de Bont ES, (2012) Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches. Crit Rev Oncol Hematol 82: 171-186.
7. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, et al. (2010) Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys 78: 555-562.
8. Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, et al. (2011) Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis 14: 481-489.
9. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
10. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820.
11. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, et al. (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol doi:10.1200/JCO.2012.42.2592.
12. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, et al. (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1: 508-523.
13. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, et al. (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3: 99ra86.
14. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, et al. (2012) Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-223.
15. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.
16. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hechts JR, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
17. Dasari A, Messersmith WA, (2010) New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 16: 3811-3818.
18. Bunney TD, Katan M, (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10: 342-352.
19. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A, (2011) Targeted therapies: how personal should we go? Nat Rev Clin Oncol 9: 87-97.
20. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, et al. (2010) Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 36: S56-S61.
21. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P, (2002) Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94: 1121-1130.
22. Hinselwood DC, Abrahamsen TW, Ekstrøm PO, (2005) BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis 26: 2553-2561.
23. Kristensen AT, Wiig JN, Larsen SG, Giercksky KE, Ekstrøm PO, (2008) Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer? BMC Cancer 8: 213.
24. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, et al. (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158: 1253-1262.
25. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S, (2012) Postoperative adjuvant chenotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 3: CD004078.
26. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, et al. (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11: 38-47.
27. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, et al. (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307: 1383-1393.
28. Jinnin M, Medici D, Park L, Limaye N, Liu Y, et al. (2008) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14: 1236-1246.
29. Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, et al. (2009) Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res 69: 5987-5995.
30. Ter Elst A, Diks SH, Kampen KR, Hoogerbrugge PM, Ruijtenbeek R, et al. (2011) Identification of new possible targets for leukemia treatment by kinase activity profiling. Leuk Lymphoma 52: 122-130.
31. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
32. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, et al. (2010) Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer 103: 1019-1024.
33. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, et al. (2010) KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 94: 76-81.
34. Davies JM, Trembath D, Deal AM, Funkhouser WK, Calvo BF, et al. (2011) Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiat Oncol 6: 114.
35. Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, et al. (2011) KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 81: 1032-1038.
36. Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, et al. (2011) Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 17: 3469-3477.
37. Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, et al. (2011) Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study. Int J Radiat Oncol Biol Phys 81: 677-683.
38. Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, et al. (2012) KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. Int J Radiat Oncol Biol Phys doi:10.1016/j.ijrobp.2012.03.048.